Special Meeting for certain mutual fund unitholders to be held on November 21, 2025 - Click here to learn more

Fixed Income Funds

Pender Corporate Bond Fund – May 2024

Highlights The Fund enjoyed one of its best performing months in May. Key contributors were Novavax convertible bonds, Fannie Mae preferred shares, Lucid Group Inc., Emergent BioSolutions, and OPKO Health Inc., along with numerous Canadian preferred shares. Two detractors were EchoStar Corp and American Tire Distributors Holdings Inc. The Pender Corporate Bond Fund enjoyed one […]

Read More
Navigating Public Distressed Credit Investing in Today’s Markets

Expertise and experience, transparency and liquidity. In this episode, we delve into the complex world of public stressed and distressed credit investing. Join Parul Garg for a discussion on investing in stressed and distressed credits in public markets, as held in the Pender Credit Opportunities Fund and in the Pender Corporate Bond Fund. Parul provides […]

Read More
Pender Corporate Bond Fund – April 2024

Highlights: Higher risk-free rates offset line-item strength in the portfolio. Positive performance in areas including cinemas helped our positions. We continue to look beyond a single macro idea to other options to generate returns. We initiated positions in the convertible bonds of Revance Therapeutics Inc. and the secured bonds of Porch Group Inc. After an […]

Read More
Pender Bond Universe Fund – Q1 2024

Highlights A strong March characterized by strength in credit lifted the Fund into positive territory for the quarter ended March 31, 2024. Key contributors included Occidental Petroleum and OPKO Health. Currently the Fund has a 22% weight in non-investment grade holdings achieved though exposure to the Pender Corporate Bond Fund units along with select non-IG […]

Read More
Pender Corporate Bond Fund – March 2024

Highlights Large positive moves came from some deeply discounted bonds including Esperion’s 2025 notes, Lucid Group’s 2026 convertible bonds, and 2028 bonds of Emergent BioSolutions. Convertible bonds in Equinox Gold (2029) and OPKO Health (2029) provided further gains. The wide valuation divergence between certain pockets in the credit markets and the tight spreads in the […]

Read More
Pender Corporate Bond Fund – February 2024

Highlights: Positive contributors included convertible notes from Esperion Therapeutics, Inc. and Bandwidth Inc., and from our position in Lucid Group. A few weak spots included our position in the credit of SSR Mining Inc due to operational challenges at that company's Copler mine in Turkey. However, we believe the credit coverage of the 2039 notes […]

Read More
Pender Corporate Bond Fund – January 2024

Highlights: Through December and January, the Fund initiated a position in the bonds of Sibanye Stillwater Ltd. which is the largest worldwide pure-play company in the mining and refining of platinum group metals. January saw a selloff in Canadian investment grade bonds and limited gains in high yield indices. Esperion Therapeutics Inc. was the Fund’s […]

Read More
Pender Bond Universe Fund – Q4 2023

Highlights The past quarter was characterized by a strong bond market reaction to the disinflationary trend. Longer dated, high grade bonds were the strongest contributors to performance. Favourable performers included Warner Brothers Discovery Inc. (2062), and US TIPS (2052). The Fund’s exposure to credit (via Pender Corporate Bond Fund) remains lower relative to historic weightings. […]

Read More
Pender Corporate Bond Fund – December 2023

Highlights: December’s outperformance was driven by some deeply discounted and distressed lines including the preferred shares of Fannie Mae and Freddie Mac which rallied more than 30%. We added to our position in McDermott International Ltd. at deeply discounted prices. Select off-the-run and unrated bonds remain extremely attractive where the value of the issuing companies […]

Read More
1 3 4 5 6 7 11

Sign Me Up

Receive a hand-picked selection of our latest insights monthly, straight to your inbox.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Email Opt In

© 2025 PenderFund Capital Management Ltd. All Rights Reserved.
crossmenuchevron-downchevron-up-circle linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram